Amarin | AMRN - Selling And Administration Expenses


Amarin reported $18.97M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025